Across the globe, countries are competing to attract international clinical trials. In this competition, contracting cycle times are increasingly recognized as key contributor to a country's attractiveness as clinical trial location.
This white paper focuses on optimizing clinical trial startup times by improving contracting efficiency. It highlights the competitive landscape in Europe, where harmonized regulatory frameworks have made startup times a crucial differentiator.
Germany's efforts to regain its position as a leading location for clinical trials are also explored, with the adoption of the National Pharmaceutical Strategy and the Medicine Research Act aimed at streamlining clinical trial processes.
The paper concludes with recommendations for countries to adopt standardized contract templates and harmonized budgeting approaches to remain competitive in attracting clinical trials, emphasizing the importance of reducing startup times to enhance a country's attractiveness as a research location.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.
.svg){kind=icon}
